Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
Posted 04 August 2017 | By
In its continued push to support the development of generic drugs, the US Food and Drug Administration (FDA) on Friday finalized 46 product-specific bioequivalence guidances.
The guidances, which lay out FDA’s expectations for the studies that should be done to demonstrate that a generic drug is bioequivalent to its reference product, give specific recommendations for what analytes to measure, what dissolution test methods and sampling times
Some of the guidances also specify the testing that can be done in order to obtain a waiver for in vivo testing, though for some products, such as valporic acid, FDA says in vivo tests should be done.
While the agency has released several batches of new and revised draft bioequivalence guidances since 2016, this is the first time the agency has finalized any bioequivalence guidances since September 2015.
Among the latest final guidances are recommendations for Gilead’s hepatitis B and HIV drug Viread (tenofovir disoproxil fumarate), multiple formulations of the antibiotic drug amoxicillin and the anti-seizure drug clonazepam.
FDA, Federal Register Notice
Tags: Bioequivalence Guidance, BE
Regulatory Focus newsletters
All the biggest regulatory news and happenings.
Regulatory Affairs Professionals Society (RAPS)
5635 Fishers Lane, Suite 400
Rockville, Maryland 20852
© 2021
Regulatory Affairs Professionals Society.